Biothera Pharmaceuticals Appoints Andrew D.C. LaFrence Chief Financial Officer
16. Mai 2018 16:10 ET
|
Biothera Pharmaceuticals, Inc.
EAGAN, Minn., May 16, 2018 (GLOBE NEWSWIRE) -- Biothera Pharmaceuticals, Inc., announced the appointment of Andrew D.C. LaFrence, CPA as Senior Vice President and Chief Financial Officer, effective...
Biothera Pharmaceuticals’ Phase 2 Study of Imprime PGG Combination Therapy in Non-Small Cell Lung Cancer Patients Published in Investigational New Drugs
24. März 2017 10:00 ET
|
Biothera Pharmaceuticals, Inc.
EAGAN, Minn., March 24, 2017 (GLOBE NEWSWIRE) -- Biothera Pharmaceuticals, Inc. today announced peer-reviewed publication of results of a randomized Phase 2 clinical study of the Company’s cancer...
Biothera Pharmaceuticals Announces Presentation of Clinical Data Supporting Use of a Patient Selection Biomarker for its Phase 2 Cancer Immunotherapy
24. Februar 2017 14:24 ET
|
Biothera Pharmaceuticals, Inc.
EAGAN, Minn., Feb. 24, 2017 (GLOBE NEWSWIRE) -- Biothera Pharmaceuticals, Inc. will present data today from all cohorts (total N=36) enrolled in a healthy human volunteer study of Imprime PGG, the...